PTGEF News Alert Portage Biotech Inc. (PTGEF) 0.1350 09/27/2014
Post# of 273322
Posted On: 09/27/2014 11:23:22 PM
Portage Biotech Inc. (PTGEF) 0.1350 $PTGEF
Portage Announces New Consultants for its PPL-003 Development Programs
PR Newswire - Tue Sep 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added two more consultants to its team for further development of its PPL-003 for uveitis. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye.
Portage Announces Proposed Private Placement
PR Newswire - Thu Sep 11, 7:57AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its preclinical development activities and financial commitments to Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" .
Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014.
Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane.
Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage" , a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U" , and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2.
Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com.
Portage Announces New Consultants for its PPL-003 Development Programs
PR Newswire - Tue Sep 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added two more consultants to its team for further development of its PPL-003 for uveitis. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye. Portage Announces Proposed Private Placement
PR Newswire - Thu Sep 11, 7:57AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its preclinical development activities and financial commitments to Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" . Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014. Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane. Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage" , a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U" , and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2. Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com. 
(0)
(0)